跳至主要内容

Medicilon assists Shijiazhuang No.4 Pharmaceutical's Class 1 new chemical drug SYN045 tablets obtain clinical approval

 


On January 26, SYN045, a Class I new drug developed by Shijiazhuang No.4 Pharmaceutical, received a clinical trial approval notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).  This marks another substantial step forward in the research and development of the company's second innovative drug.

Shanghai Medicilon Inc. (Medicilon), as a partner of Shijiazhuang No.4 Pharmaceutical, provided preclinical research services such as pharmacokinetics and safety evaluation for the development of SYN045 tablets, helping to successfully obtain approval.

SYN045 is a Class I new drug independently developed by Shijiazhuang No.4 Pharmaceutical.  SYN045 is a selective long-acting PGI2 receptor agonist and is intended to be used for pulmonary arterial hypertension.  Preclinical studies have shown that SYN045 has good target selectivity, compound activity, and safety.

Currently, Medicilon's preclinical research service platform has established a research operation process and quality system that complies with international standards and has a laboratory of 29,000 square meters.  Medicilon has also obtained NMPA drug GLP laboratory certification qualification and complies with the GLP laboratory standards of the US FDA, Australian TGA, and EU EMEA.  The animal experiment facility has passed the International Laboratory Animal Assessment and Accreditation (AAALAC) and can simultaneously raise non-human primates, dogs, rats, rabbits, guinea pigs, mini pigs and other experimental animals, and can provide services such as pharmacological efficacy, pharmacokinetic research and safety evaluation.

About Shijiazhuang No.4 Pharmaceutical

Shijiazhuang No.4 Pharmaceutical is a large-scale high-tech pharmaceutical enterprise that develops collaboratively with R&D and industrialization in multiple fields of the industry chain including innovative drugs, generic drugs, specialty APIs, high-end preparations and pharmaceutical packaging materials.  Shijiazhuang No.4 Pharmaceutical ranks among the top 100 enterprises in China's pharmaceutical industry and among the outstanding brand enterprises exporting preparations in China's chemical and pharmaceutical industry.  In 2007, the company was listed on the HKEX (SSY Group 02005.HK).

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of June 2023, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 420 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文